Hospital Affairs Lead
Pubblicato il 10-09-2026 - Rhythm Pharmaceuticals in Napoli
Company Overview Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful support for healthcare providers and patients and their families. We recognize the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to learn, adapt, and our tenacity to overcome barriers, together.
Opportunity Overview As a member of the Rhythm Italy field-based team, you will be working within the field of rare MC4R pathway diseases. As the Hospital Affairs Lead (HAL), you will own sales responsibility for our product in Italy across its approved indications,
work collaboratively within the National and International team to lead the sales strategy and serve as a trusted commercial partner to external experts and decision makers through scientific expertise, project management, network formation and service offerings.
Responsibilities and Duties Have regional sales responsibility for our product
Develop strong partnerships with key external experts, payers and multidisciplinary stakeholders
Deliver growth in line with expectations for the Italian business
Support development and expansion of comprehensive care programs and patient support programs
Facilitate referral pathways between peripheral sites and prescribing centers
Lead an omnichannel customer approach relevant for customer segmentation and individual customer preferences/objectives
Accountable for using CRM system for business planning
Challenge current practice to deliver the best outcomes for patients
Be able to discuss benefits of clinical data to improve the lives of patients (in line with approved in